Hang Seng Biotech ETF E-Fangda announced that due to the suspension of trading of the target index securities Minimally Invasive Healthcare and Minimally Invasive Robot-B from September 1, 2026, the price may fluctuate greatly after the resumption of trading and affect the net asset value of the fund. After agreement with the fund custodian, starting September 2, 2026, when investors purchase and redeem the fund, the settlement of the subscription cash replacement refund and redemption cash replacement amount corresponding to the above two securities will be handled according to the actual transaction cost after the resumption of trading or the price deemed reasonable by the fund manager, excluding interest, if any, occurs during the period Equity changes such as stock transfers will be adjusted accordingly and repeated No further announcements will be made after the cards.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.